We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Effect of Curcumin on Systemic Lupus Erythematosus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03953261
Recruitment Status : Terminated (COVID and lack of support staff 2. lack of support staff to conduct the study)
First Posted : May 16, 2019
Last Update Posted : August 5, 2022
Information provided by (Responsible Party):
Loma Linda University

Brief Summary:
The purpose of this investigator initiated study is to determine the efficacy of curcumin on disease activity of subjects with systemic lupus erythematous. Curcumin has been found to have anti-inflammatory effects and has been found to improve disease activity in lupus patients. In addition, subjects with rheumatoid arthritis as well as osteoarthritis have also found benefit for their disease activity.

Condition or disease Intervention/treatment Phase
Systemic Lupus Erythematosus Drug: Curcumin supplement Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Curcumin on Systemic Lupus Erythematosus
Actual Study Start Date : September 1, 2019
Actual Primary Completion Date : April 13, 2022
Actual Study Completion Date : April 13, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lupus
Drug Information available for: Curcumin

Arm Intervention/treatment
Experimental: Curcumin Drug: Curcumin supplement
Intervention is 2 grams of curcumin supplement per day

Placebo Comparator: Placebo Drug: Curcumin supplement
Intervention is 2 grams of curcumin supplement per day

Primary Outcome Measures :
  1. Change in SLEDAI [ Time Frame: 90 days ]
    Number of participants with change in SLEDAI by 2 points by Day 90

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 18 or older
  • Diagnosed with Systemic Lupus Erythematous according to the 2012 Systemic Lupus International Collaborating Clinics Classification Criteria.
  • SLEDAI score of 6 or higher
  • Ability to take oral medication and be willing to adhere to the study drug regimen

Exclusion Criteria:

  • Inability to provide written consent for study participation
  • Use of curcumin supplements within 30 days of enrollment of study
  • Liver function disorders (AST/ALT > 2.5x upper limit of normal)
  • Pregnancy or lactation
  • Known allergic reactions to turmeric
  • Subjects who are admitted for recent hospitalization within past 60 days
  • Treatment with another investigational drug or other intervention within past 60 days
  • Subjects with end stage renal disease on dialysis
  • Subjects who lack the ability to provide consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03953261

Layout table for location information
United States, California
Loma Linda University
Loma Linda, California, United States, 92354
Sponsors and Collaborators
Loma Linda University
Layout table for additonal information
Responsible Party: Loma Linda University
ClinicalTrials.gov Identifier: NCT03953261    
Other Study ID Numbers: 5190041
First Posted: May 16, 2019    Key Record Dates
Last Update Posted: August 5, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action